Cure My Disease

Don't miss your cure!

 Log in / Sign up

New hope for lymphoma patients: glofitamab studied in Real-World setting

NCT ID NCT07200375

Disease control Sponsor: Hoffmann-La Roche Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Sep 09, 2026 · Updated 5 times

Summary

This study is observing how well the drug glofitamab works and how safe it is for Chinese adults with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) who have already tried one prior treatment. Researchers will track 300 participants receiving glofitamab as part of their normal cancer care to see how long they live without the cancer getting worse and how many achieve complete remission.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Glofitamab
What this could lead to
If successful, this study could confirm that glofitamab is an effective second-line treatment for relapsed or refractory DLBCL in real-world Chinese patients.
What could go wrong
This is an observational study, not a controlled trial, so results may be less definitive. Glofitamab can cause serious side effects like cytokine release syndrome.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 300 people

The number the study aims to enrol. It can still change while the study runs.

Started

Sep 2025

Expected to finish

Sep 2029

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Adult Chinese participants with R/R DLBCL who will be treated with a glofitamab-based regimen either after enrollment into the study or within 90 days prior to enrollment.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Histologically confirmed R/R DLBCL after one line of systemic therapy * Will be treated with Glofit-based regimen (known as being recommended and having the intention to be treated with Glofitamab at the time of signing ICF) or have initiated Glofit-based regimen treatment within three months (90 days) prior to enrollment Exclusion Criteria: * Participants who currently participate in or plan to participate in any interventional clinical trial

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Diffuse large B-cell lymphoma are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

diffuse large B-cell lymphoma relapsed/refractory diffuse large B-cell lymphoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Diffuse large B-cell lymphoma

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    22 sites in 2 countries. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Cancer Hospital Chinese Academy of Medical Sciences.

    RECRUITING

    Langfang, Hebei, 065001, China

  • Chinese Academy of Medical Sciences Hematology Hospital;Lymphoma Diagnosis and Treatment Center

    RECRUITING

    Tianjin, Tianjin Municipality, 301636, China

  • Guangdong Provincial People's Hospital

    RECRUITING

    Guangzhou, 510080, China

  • Harbin Medical University Cancer Hospital

    RECRUITING

    Harbin, 150081, China

  • Henan Cancer Hospital

    RECRUITING

    Zhengzhou, 450008, China

  • Peking University People's Hospital

    RECRUITING

    Beijing, 100044, China

  • Peking University Third Hospital

    RECRUITING

    Beijing, 100191, China

  • Prince of Wales Hospital

    RECRUITING

    Hong Kong, Hong Kong

  • Queen Mary Hospital

    RECRUITING

    Hong Kong, Hong Kong

  • Ruijin Hospital, Shanghai Jiaotong University School of Medicine

    RECRUITING

    Shanghai, 200025, China

  • Shandong Cancer Hospital

    RECRUITING

    Jinan, 250117, China

  • Shanghai Sixth People's Hospital Affiliated to Shanghai Jiao Tong University School of Medicine

    RECRUITING

    Shanghai, 200233, China

  • The First Affiliated Hospital of Ningbo University

    RECRUITING

    Ningbo, 315000, China

  • The First Affiliated Hospital of Wenzhou Medical University

    RECRUITING

    Wenzhou, 325035, China

  • The First Affiliated Hospital of Xian Jiao Tong University

    RECRUITING

    Xi'an, 710061, China

  • The First Bethune Hospital of Jilin University

    RECRUITING

    Changchun, China

  • The Second Affiliated Hospital of Nanchang University

    RECRUITING

    Nanchang, 330008, China

  • Tianjin Cancer Hospital

    RECRUITING

    Tianjin, 300060, China

  • Tongji Hospital affiliated to Tongji Medical College of Huazhong University of Science & Technology

    RECRUITING

    Wuhan, 430030, China

  • West China Hospital of Sichuan University

    RECRUITING

    Chengdu, 610041, China

  • Xiehe Hospital, Tongji Medical College Huazhong University of Science & Technology

    RECRUITING

    Wuhan, 430022, China

  • Yantai Yu Huangding Hospital

    RECRUITING

    Yantai, 264099, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.